MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S. ., Jhund, P. S., … McAlister, F. A. (2010). Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. http://doi.org/10.2337/dc09-2227
S. Majumdar
First name
S.
Middle name
R.
Last name
Majumdar
Padwal, R. S., Klarenbach, S. W., Wang, X. ., Sharma, A. M., Karmali, S. ., Birch, D. W., & Majumdar, S. R. (2013). A simple prediction rule for all-cause mortality in a cohort eligible for bariatric surgery. JAMA Surg. http://doi.org/10.1001/jamasurg.2013.3953
Gamble, J. M., Thomas, J. M., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2016). Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine (Baltimore). http://doi.org/10.1097/md.0000000000003995
Gamble, J. M., Chibrikov, E. ., Twells, L. K., Midodzi, W. K., Young, S. W., MacDonald, D. ., & Majumdar, S. R. (2017). Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(16)30316-3
Gamble, J. M., Donnan, J. R., Chibrikov, E. ., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2018). The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study. Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2017.12.008
Gamble, J. M., Chibrikov, E. ., Midodzi, W. K., Twells, L. K., & Majumdar, S. R. (2018). Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink. BMJ Open. http://doi.org/10.1136/bmjopen-2018-023830
Gamble, J. M., Donnan, J. R., Chibrikov, E. ., Twells, L. K., Midodzi, W. K., & Majumdar, S. R. (2018). Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. Sci Rep. http://doi.org/10.1038/s41598-018-33483-y